P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study)
Titel:
P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study)
Auteur:
Zander, Thilo Pabst, Thomas Schär, Sämi Aebi, Stefan Pabst, Tobias Mey, Ulrich Novak, Urban Lerch, Erika Rhyner, Gaëlle Goede, Jeroen Maniecka, Zuzanna Hayoz, Stefanie Rufer, Axel Renner, Christoph Driessen, Christoph